A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is some information available that indicates that Milk Thistle is an effective treatment for liver disease. This study will compare Milk Thistle with a placebo, (a medicine that looks just like Milk Thistle but does not contain any Milk Thistle) to see if people with both Hepatitis C and HIV infections show improvement or cure of Hepatitis C. The study will last one year.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluating Silymarin for Chronic Hepatitis C

NCT00030030

Hepatitis C, Chronic

COMPLETED PHASE2

Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C

NCT01292161

Hepatitis C

COMPLETED PHASE2

Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults

NCT01472354

Hepatitis c

COMPLETED NA

Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C

NCT01018615

Chronic Hepatitis C Oxidative Stress

COMPLETED PHASE1

Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.

NCT02641158

Hepatitis C HIV AIDS +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with many different diseases are requesting information from health care providers, (physicians and nurses) about alternative therapies. The paucity of evidence based information requires that rigidly structured clinical trials comparing dietary supplements, herbal products and other alternative modalities with either placebo or standard of care be conducted in a timely fashion. There is a body of evidence that Silymarin is both well tolerated and efficacious for the treatment of Hepatitis C. In patients co-infected with HIV \& HCV, treatment choices are sometimes limited by intolerable toxicities of standard therapies for the treatment of HCV when combined with antiretroviral therapy for treatment of HIV. This study will seek to determine if Silymarin, an herbal product that is widely used, will be well tolerated and effective in slowing progression of liver damage in patients co-infected with HIV \& HCV.

The Informed Consent Document contains all the required elements of informed consent as required by 21CFR50. The consent clearly states that this is research, participation is voluntary and that treatment with Silymarin may not be effective. Every effort has been made to outline whatever is known about any side effects. There are very few. All study participants are followed closely, are given their test results which are also shared with primary care providers. The investigators have convened a Data and Safety Monitoring Board and the Mount Sinai IRB has approved and will monitor the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Silymarin

Group Type EXPERIMENTAL

Silymarin

Intervention Type DRUG

Silymarin (milk thistle)

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Silymarin

Silymarin (milk thistle)

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women 18 years old and older
* Blood tests that are positive for a certain type of Hepatitis C known as
* HIV +
* Blood tests for liver function that indicate that the liver is working - must be obtained within one month of study entry
* CD4 counts and HIV viral loads obtained within one month of study entry
* (CD4 count \<100 - eligible if HIV Viral Load \<25,000)
* (CD4 \>100 - eligible with any HIV Viral Load)

Exclusion Criteria

* Women who are pregnant \& breast-feeding \& male partners of pregnant women
* Diagnosis of advanced liver disease
* Chronic liver disease other than Hepatitis C
* HIV related infection within two weeks of study entry
* Having had any organ transplant in the past including bone marrow
* History of mental illness including depression within three months of study entry and attempted suicide or hospitalization for the treatment of mental illness at any time in the past
* Chemotherapy treatment or treatment with steroids or other drugs that affect the immune system within six months of study entry
* Problems with alcohol of illegal drugs within one year of study entry. Patients on methadone will be allowed to enter the study.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No